Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
May 12, 2022Targovax ASA: First quarter 2022 results
May 11, 2022Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial
May 11, 2022Targovax to present at upcoming conferences
May 10, 2022Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma